Plato Investment Management Ltd Raises Holdings in Illumina, Inc. (NASDAQ:ILMN)

Plato Investment Management Ltd increased its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 238.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,795 shares of the life sciences company's stock after purchasing an additional 9,722 shares during the period. Plato Investment Management Ltd's holdings in Illumina were worth $1,797,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of ILMN. UMB Bank n.a. boosted its holdings in shares of Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company's stock valued at $140,000 after acquiring an additional 88 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock valued at $585,000 after buying an additional 90 shares during the last quarter. Carson Advisory Inc. grew its holdings in Illumina by 3.8% during the 3rd quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company's stock worth $360,000 after acquiring an additional 102 shares during the last quarter. Institute for Wealth Management LLC. lifted its holdings in Illumina by 4.6% during the 2nd quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company's stock worth $285,000 after buying an additional 119 shares during the period. Finally, Platform Technology Partners raised its position in shares of Illumina by 4.2% during the third quarter. Platform Technology Partners now owns 3,512 shares of the life sciences company's stock worth $458,000 after acquiring an additional 141 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

Shares of ILMN traded down $7.19 during trading hours on Friday, reaching $135.05. 4,740,357 shares of the company's stock traded hands, compared to its average volume of 2,019,896. Illumina, Inc. has a 12 month low of $92.69 and a 12 month high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The stock has a market cap of $21.42 billion, a PE ratio of -13.76 and a beta of 1.13. The firm's 50 day simple moving average is $139.44 and its 200-day simple moving average is $124.23.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business's quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.33 EPS. Equities analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ILMN. Morgan Stanley reissued an "equal weight" rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday. Barclays increased their target price on Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Daiwa America upgraded Illumina to a "strong-buy" rating in a research note on Friday, August 16th. TD Cowen upped their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Finally, UBS Group increased their price target on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of "Moderate Buy" and a consensus price target of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.